2025-12-31 - Analysis Report
Okay, let's break down the analysis of Natera Inc. (NTRA) stock.

**Company Overview:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing, primarily focusing on prenatal testing, cancer diagnostics, and organ health.

**1. Return Rate Comparison & Alpha/Beta Analysis:**

*   **NTRA Cumulative Return:** 135.64%
*   **S&P 500 (VOO) Cumulative Return:** 102.47%
*   **Divergence:** 36.0 (Relative Divergence: 47.3)
*   **Analysis:** NTRA has significantly outperformed the S&P 500 in cumulative return. The divergence of 36.0, with a relative divergence of 47.3, suggests that the current divergence is in the middle of its historical range. This means that while NTRA has performed better than the S&P 500, its current outperformance is not at an extreme relative to its past fluctuations.

*   **Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | -10.0%  | 70.1%   | -34.0%  | -0.2   | 1.2    |
| 2016-2018  | 22.0%   | 80.0%   | 6.0%    | 0.1    | 1.9    |
| 2017-2019  | 50.0%   | 80.0%   | 28.0%   | 1.0    | 4.7    |
| 2018-2020  | 186.0%  | 80.5%   | 163.0%  | 1.1    | 13.9   |
| 2019-2021  | 96.0%   | 80.5%   | 49.0%   | 1.6    | 13.0   |
| 2020-2022  | -77.0%  | 80.5%   | -76.0%  | 0.1    | 5.6    |
| 2021-2023  | -194.0% | 76.6%   | -195.0% | -1.1   | 8.7    |
| 2022-2024  | 8.0%    | 76.6%   | -13.0%  | -1.2   | 22.1   |
| 2023-2025  | 163.0%  | 76.6%   | 96.0%   | 0.1    | 32.1   |

*   **Analysis of Alpha/Beta Table:**
    *   **CAGR Variability:** The Compounded Annual Growth Rate (CAGR) shows significant volatility, ranging from -194% to +186%. This highlights the stock's high growth potential but also substantial risk.
    *   **High MDD:**  The Maximum Drawdown (MDD) is consistently high, indicating significant potential for loss from peak to trough during these periods.
    *   **Alpha:** Alpha, representing excess return relative to the market, varies widely. Positive Alpha indicates outperformance, while negative Alpha suggests underperformance. The most recent period (2023-2025) shows a strong positive Alpha, suggesting recent market outperformance.
    *   **Beta:** Beta fluctuates around 1, indicating market-average volatility in some periods, and above/below average volatility in others. Periods with higher Beta values (e.g., 2019-2021) suggest the stock is more sensitive to market movements. Negative betas are particularly unusual.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 229.98
*   **Previous Close:** 231.3
*   **Change:** -0.57
*   **5-day SMA:** 233.192
*   **20-day SMA:** 233.6335
*   **60-day SMA:** 210.6322

*   **Analysis:** The price has slightly decreased recently. The 5-day and 20-day SMAs are above the current price, suggesting a potential short-term downward trend or consolidation.  The 60-day SMA is significantly lower, indicating a longer-term upward trend.

**3. RSI, PPO, & MRI Analysis:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 40.53
*   **PPO:** -0.681
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)
*   **Recent Divergence Change:** 2.0 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -49.9%

*   **Analysis:**
    *   **MRI:** The high MRI suggests the model considers the stock a good investment at this time based on its risk-reward profile.
    *   **RSI:** The RSI of 40.53 indicates that the stock is not overbought or oversold.
    *   **PPO:** The negative PPO suggests a slight downward trend in momentum.
    *   **Hybrid Signal:** The hybrid signal recommends a full allocation to the stock, reinforcing the positive outlook.
    *   **Recent Divergence Change:** The recent increase in relative divergence signals short-term upward momentum.
    *   **Expected Return:** The significantly negative expected return is concerning and contradicts other indicators. It suggests that the model forecasts a significant underperformance relative to the S&P 500 over the long term (more than 2 years).

**4. Recent News & Significant Events:**

*   **Positive Headlines:**
    *   Medical Stock Hovers Near Buy Point After 46% Gain.
    *   Analysts Are Bullish on These Healthcare Stocks.
    *   Barclays Raises Natera (NTRA) Price Target to $270.
    *   SWS Partners bought shares of NTRA.
*   **Notable Investor:**
    *   Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (includes NTRA).
*   **Positive Commentary:**
    *   This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now (includes NTRA).

*   **Analysis:**  The recent news is overwhelmingly positive, featuring analyst upgrades, institutional buying, and inclusion in the portfolios of successful investors. This positive sentiment could drive further price appreciation.

**4-2. Analyst Opinions:**

*   **Consensus:** Strong Buy (1.47)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** $246.26 / $285.00 / $186.00

*   **Analysis:** A strong buy consensus from a significant number of analysts further supports a positive outlook.  The average target price ($246.26) is above the current price, suggesting potential upside. The high target of $285 reinforces this potential.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-11-07 | -0.64 | 0.59 B$   |
| 2025-08-08 | -0.74 | 0.55 B$   |
| 2025-05-09 | -0.5  | 0.50 B$   |
| 2024-11-12 | -0.26 | 0.44 B$   |
| 2025-11-07 | -0.26 | 0.44 B$   |

*   **Analysis:** The table shows a consistent pattern of negative EPS (Earnings Per Share), indicating that the company is not currently profitable.  However, revenue has been generally increasing, suggesting growth in the company's operations. The most recent earnings are better than the previous three quarters.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.59B  | 64.91%        |
| 2025-06-30   | $0.55B  | 63.41%        |
| 2025-03-31   | $0.50B  | 63.12%        |
| 2024-12-31   | $0.48B  | 62.94%        |
| 2024-09-30   | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-09-30   | $1.25B  | -6.99%   |
| 2025-06-30   | $1.25B  | -8.10%   |
| 2025-03-31   | $1.24B  | -5.40%   |
| 2024-12-31   | $1.20B  | -4.50%   |
| 2024-09-30   | $0.88B  | -3.60%   |

*   **Analysis:**
    *   **Revenue:** Revenue is steadily increasing quarter over quarter, indicating strong sales growth.
    *   **Profit Margin:** The high profit margins suggest that the company is efficiently managing its costs of goods sold.
    *   **Equity:** Equity is increasing, showing the company is growing in value.
    *   **ROE:** The negative Return on Equity (ROE) reflects the current unprofitability, but it is trending upwards.

**7. Comprehensive Analysis (Summary):**

Natera Inc. presents a mixed investment picture:

*   **Positives:**
    *   Historically strong outperformance relative to the S&P 500, although the current divergence is within its historical range.
    *   Positive recent news and analyst sentiment (Strong Buy consensus, target price above current price).
    *   Increasing revenue and high profit margins.
    *   Increasing equity.
    *   Short-term positive price movement (recent divergence change).
    *   High Market Risk Indicator suggests a favorable risk/reward.
*   **Negatives/Concerns:**
    *   Consistent unprofitability (negative EPS and ROE).
    *   High historical Maximum Drawdown (MDD) indicates significant potential for losses.
    *   The long-term negative Expected Return of -49.9% contradicts other indicators and requires further investigation.
    *   Beta fluctuates, can be more volatile than the market as a whole.

**Conclusion:**

NTRA is a high-growth, high-risk stock. Recent positive momentum and strong analyst sentiment make it attractive for investors seeking growth, but the consistent unprofitability and potential for large drawdowns need to be carefully considered. The contradictory long-term expected return warrants further due diligence. It's also recommended to compare Natera to other competing companies to estimate the value better.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.